cell-therapy
5 stories related to this topic, newest first.
ncbi.nlm.nih.govMacrophage infusions linked to lower death and transplant rates in cirrhosis patients
A study published in Cell Stem Cell reports that infusions of macrophages were associated with reduced mortality and fewer liver transplants among people with cirrhosis. The findings come from research led by P. N. Brennan and colleagues.
StatFDA Approves BeOne Medicines’ Beqalzi for Relapsed/Refractory Mantle Cell Lymphoma
BeOne Medicines received FDA approval for its BCL-2 inhibitor Beqalzi to treat relapsed or refractory mantle cell lymphoma. The drug is the first BCL-2 inhibitor specifically cleared for this indication in the U.S. Separately, CREATE Medicines raised $122 million to advance its i…
benzinga.comMiNK Therapeutics Reports agenT-797 Produces Context-Dependent Immune Responses in Cancer and ARDS
MiNK Therapeutics presented clinical data at the ASGCT 2026 meeting showing its off-the-shelf iNKT cell therapy agenT-797 drove different immune responses in patients with solid tumors and those with acute respiratory distress syndrome. The same product batch from one donor activ…
Adrian McArdle, M.B, B.Ch., Kshemendra Senarath-Yapa, M.B.B.Chir., Graham G. Walmsley, B.S., Michael Hu, M.D., M.P.H., David A. Atashroo, M.D.,Ruth Tevlin, M.B., B.Ch.,Elizabeth Zielins, M.D.,Geoffrey C. Gurtner, M.D., Derrick C. Wan, M.D., and Michael T. Longaker, M.D., F.A.C.S. / Wikimedia (CC BY-SA 4.0)Nkarta Receives Approval for Outpatient Dosing in Lupus Nephritis Trial
Nkarta announced that regulators have approved a protocol change allowing outpatient dosing of its NKX019 therapy in lupus nephritis trials, reducing patient monitoring time to two hours. Following this update, Nkarta's stock price increased by approximately 13%.
Substrate placeholder — needs reviewWoman with Rare Combination of Three Autoimmune Diseases Reports No Symptoms After Engineered Immune Cell Treatment
A woman diagnosed with an ultra-rare combination of three autoimmune diseases received a single dose of engineered immune cells. She has experienced no symptoms since the treatment. The case was reported in a medical journal.